Covering weight-loss drugs at their current prices would cost U.S. health programs more than the savings seen from the medications’ benefits, Noelia Duchovny, a Congressional Budget Office analyst, said in a U.S. National Academies workshop, Bloomberg reports. “CBO expects that at their current prices, (anti-obesity medications) would cost the federal government more than it would save from reducing other health-care spending – which would lead to an overall increase in the deficit over the next 10 years,” Duchovny said, according to Bloomberg. “CBO is not aware of empirical evidence that directly links the use of AOMs to reductions in other health-care spending,” the analyst added. Shares of Eli Lilly (LLY) are down $4.10 to $768.75 following the comments while Novo Nordisk (NVO) is down 49c to $130.88.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- J.P. Morgan Pounds the Table on Eli Lilly Stock
- Eli Lilly Stock (NYSE:LLY): Bullish on Innovation and Pharmaceutical Success
- Oprah to host TV special discussing weight loss, CNN reports
- Eli Lilly’s (NYSE:LLY) Weight-Loss Drug Outshines Wegovy for First Time
- JPMorgan biotech/pharma analysts hold an analyst/industry conference call